Search

Your search keyword '"Bergamo, F."' showing total 523 results

Search Constraints

Start Over You searched for: Author "Bergamo, F." Remove constraint Author: "Bergamo, F."
523 results on '"Bergamo, F."'

Search Results

1. Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience

2. Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study

3. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

4. OC.04.2: EFFECT OF PREOPERATIVE CHEMO-RADIATION ON TUMORINFILTRATING LYMPHOCYTES IN LOCALLY ADVANCED RECTAL CANCER AND TUMOR RESPONSE: RESULTS FROM THE STAR-01 COHORT

5. ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients

7. Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study

8. 88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

9. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

10. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

12. Prognostic value of Body Mass Index in stage II/III colon cancer: post-hoc analysis from the TOSCA trial

14. The immune microenvironment in pancreatic ductal adenocarcinoma: a potential preoperative marker of lymphnodal involvement

15. 59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications

16. LBA22 Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study

17. 1273P Early integration between oncologic treatment and palliative care: Experience of the simultaneous care outpatient clinic at Veneto Institute of Oncology, ESMO Designated Center

18. 422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018)

19. 370P Trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: The HERACLES RESCUE phase II trial

20. 399P Role of geriatric assessment and oncological multidimensional prognostic index in elderly patients with metastatic colorectal cancer in a real-world setting

21. 1209P A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort

22. 413P Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT) + bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies

23. 341P Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study

24. 367P Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings from the PARERE study

25. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

26. SO-36 An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study

31. Correction: miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer (British Journal of Cancer, (2020), 122, 9, (1354-1366), 10.1038/s41416-020-0773-2)

32. 467P Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial

33. 47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01

34. O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study

35. 1666P Non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-Institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI)

36. 1664P Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort

37. 575P Impact of immunological alterations and post-operative biomarkers on long-term outcomes in patients with locally advanced rectal cancer: Results from the STAR-01 study cohort

39. 124P Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)

40. Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study

42. O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO

44. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

45. SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)

46. SO-27 Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO

49. P-57 Atezolizumab in combination with bevacizumab in patients with unresectable HCC previously untreated with systemic therapy: Interim analysis results from phase IIIb Italian AMETHISTA trial

Catalog

Books, media, physical & digital resources